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ABSTRACT (250 Words) 
 
Objective: The Fontan operation greatly improves survival for single ventricle congenital 
heart disease patients but creates a physiology that leads to long-term multi-organ 
dysfunction. A non-invasive screening tool that can identify impending decline is sought.  
The objective of this pilot study was to assess the microcirculation in Fontan-palliated 
patients by measuring tissue oxygen saturation (StO2) in superficial and deeper tissues.  
Approach: Three patient cohorts were studied: Fontan group (n=8) and two patient control 
groups, liver disease group (n=8) and tetralogy of Fallot group (n=9). 22 healthy controls 
were also examined.  Superficial and deeper StO2 was measured at the forearm, thenar 
eminence, index and ring fingers of both arms using the LEA O2C spectrophotometry 
device.  
Main Findings: Superficial StO2 was reduced in Fontan patients compared to healthy 
controls (p=0.002) and tetralogy patients (p=0.016), but not compared to the liver group 
(p=0.313). Deeper StO2 was similar between groups (p=0.112). The gap between deeper 
and superficial StO2 was raised in Fontan patients compared to healthy controls (p=0.001) 
and tetralogy patients (p=0.037), but not compared to the liver group (p=0.504). There was 
no clinically relevant difference in StO2 between the left and right arms, and the variation in 
StO2 according to measurement site was similar between the four groups.  
Significance: Vascular optical spectrophotometry  is a feasible non-invasive measure of 
micro-circulatory function that can easily be performed in the clinic setting and may have 
utility in patients with Fontan circulations. Further, we provide important normal range data in 
the healthy control population which can be used to design future studies.  
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INTRODUCTION 
 
The most complex and rare forms of congenital heart disease (CHD) are those conditions 
that are characterised by the presence of only one functional ventricle. Tricuspid atresia, 
double inlet left ventricle and hypoplastic left heart are some examples, which together occur 
in around 16 per 100 000 children and 2 per 100 000 adults in the UK.1 The prognosis of 
these conditions was dismal until the development of the Fontan palliation, a staged surgical 
repair that provides pulmonary blood flow through passive venous return directly from the 
vena cavae and reserves the single functional ventricle to support the systemic circulation 
(see Figure 1).2 In the UK around 200 Fontan operations are performed per year.3 Although 
a relatively small number, these patients are of increasing concern because of their high 
healthcare utilisation and also the predicament they present with late onset multi-organ 
morbidity that creates difficulties for extended palliation through heart transplant.4–6 
Documented complications include plastic bronchitis, protein losing enteropathy, liver 
disease including cirrhosis, portal hypertension, hypervascular nodules and hepatocellular 
carcinoma, chronic venous insufficiency and renal disease.7,8 It is not fully known why this 
morbidity occurs; lack of pulsatility in the venous circulation and arterial vasoconstriction with 
elevated systemic vascular resistance occurring in reponse to relatively fixed cardiac output 
are both hypothesised to underlie these problems.5,6,9 Fontan patients also demonstrate 
endothelial dysfunction, which may contribute to vasoconstriction as well as the pro-
coagulant phenotype observed in this cohort.10–13 Measures of endothelial dysfunction have 
been correlated with measures of functional health status in this group and thus may have 
prognostic value.13 The features of Fontan physiology failure are heterogeneous and difficult 
to predict. A clinical measurement that would allow monitoring of the progression of Fontan 
physiology failure and allow identification of impending decompensation would be of 
significant clinical benefit. 
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Figure 1. A) normal biventricular circulation and B) Fontan circulation 
 
  Microvascular dysfunction has been demonstrated and suggested as a biomarker in 
a range of conditions such as coronary artery disease, heart failure, systemic sclerosis and 
diabetes.14,15  The microcirculation can be assessed non-invasively by measurement of 
tissue oxygen saturation (StO2), which is the oxygen saturation of haemoglobin within a 
tissue bed. This reflects the balance between oxygen delivery and consumption in the 
assessed tissue.16 The LEA O2C device uses micro-light guided spectrophotometry to 
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simultaneously measure StO2 at depths estimated at ~2 mm, with capability to assess skin 
microcirculation e.g. venular plexus and ~6 mm in deeper tissues.17 The measurement is 
derived from blood vessels smaller than 100µm in diameter, which includes arterioles, 
capillaries, and venules.18 It does not require the vessel to be pulsatile to work and it can 
measure oxygen saturation accurately at low levels unlike pulse oximetry. Previous studies 
have demonstrated the prognostic value of StO2 measurements in situations of 
cardiovascular dysfunction. A prospective study19 recruited stable chronic heart failure 
patients and measured their superficial StO2 (1 mm depth) using the O2C device. After 6 
months, they found that patients who experienced adverse outcomes had lower baseline 
StO2 measurements compared to those who remained stable (44.8% vs 62.9%, p = 0.015). 
A meta-analysis20 reported that in sepsis patients, StO2 is significantly lower in non-survivors 
compared to survivors (74.5% vs 81.7%, p = 0.020). 
The aim of this pilot study was to assess the microcirculation in Fontan patients and 
compare their findings with relevant patient groups.  A group with tetralogy of Fallot was 
compared; these patients have also undergone childhood cardiac surgical repair and 
experience ventricular dysfunction in later life like Fontan patients21 but have a biventricular 
circulation, more aligned to a conventional heart failure phenotype. A  group with isolated 
liver disease and no primary cardiac pathology was compared; Fontan patients universally 
exhibit advanced liver disease and it is not clear how this influences other organ systems 
and their decline.22  A healthy cohort was also studied. 
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METHODS 
 
Study Population 
Healthy controls were recruited from the Newcastle University campus and the Freeman 
Hospital by advertisement. Patients were identified from departmental databases and 
approached at routine clinic appointments. Four groups of adult subjects (>18 years) were 
included in this study: healthy controls, patients with Fontan circulation (Fontan group), 
patients with repaired tetralogy of Fallot (Tetralogy group), and patients with isolated liver 
disease (Liver group) (Figure 2A).  
 
 
Figure 2. A) The four diagnostic groups included in this study. B) The LEA O2C device. C) Locations of 
StO2 measurement on the arm.  
 
Ethical Approval 
Ethical approval for patients was granted by the Proportionate Review Sub-Committee of the 
Health and Social Care Research Ethics Committee B (HSC REC B) (Ref:17/NI/0247). For 
the study of healthy subjects, ethical approval was granted by Faculty of Medical Sciences 
Research Ethics Committee, Newcastle University (Ref:1474/3891). All subjects gave written 
informed consent for inclusion in the study. 
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Study Protocol  
Measurements were conducted at the Microvascular Facility within the Northern Medical 
Physics and Clinical Engineering department at the Freeman hospital, Newcastle Hospitals 
NHS Foundation Trust. Room conditions were controlled for all subjects, including 
thermostatically controlled ambient temperature (23.5oC). Subjects were asked to refrain 
from consuming coffee or smoking on the day of their appointment. After 30 minutes of 
acclimatisation StO2 measurements were carried out. 
 
Tissue Oxygen Saturation (StO2 ) Measurements  
The LEA O2C device (LEA Medizintechnik GmbH) (Figure 2B) was used to measure 
superficial and deep StO2 levels in this study using a LF2 optical probe. The probe was 
calibrated in ambient room lighting before each subject’s measurements. StO2 was 
measured in superficial and deeper tissue at the forearm (2 cm distal to the antecubital 
fossa), thenar eminence, index fingertip, and ring fingertip in both arms (Figure 2C). After the 
probe was placed on the skin, a 15 second period was allowed for measurements to 
stabilise before they were recorded. Three sets of measurements were recorded at each 
site, and an average of the readings was used for further analysis.  
 
Statistical Analysis 
Normality of data was assessed using the Shapiro-Wilk test. Normal data is presented as 
mean with standard deviation and non-normal data as median with inter-quartile range. 
Categorical data is presented as absolute number and percentage.  To compare superficial 
and deeper StO2 between right and left arms, measurements at all four sites were averaged 
for each arm and compared within groups using the paired Student t-test for normal data and 
the Wilcoxon matched pair signed rank test for non normal data. To compare  superficial and 
deeper StO2 and the difference between the two according to diagnostic group, an average 
of superficial and deeper measurements from all sites on both arms was made and the 
difference calculated. Diagnostic groups were compared using one-way ANOVA where data 
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was normally distributed, and Kruskall-Wallis test where data was not-normally distributed. If 
a significant difference was observed, appropriate post-hoc testing was conducted using 
Tukey’s test for normal data and Dunn’s test for non-normal data, both of which account for 
multiple comparisons. A p-value of <0.05 was considered statistically significant. Prism 7 by 
GraphPad was used to conduct all statistical analyses in this study.  
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RESULTS 
 
Study population 
47 subjects completed the study protocol; 22 in the healthy control group, 8 in the Fontan 
group, 9 in the tetralogy group, and 8 in the liver group (Figure 2A). Demographic 
information is presented in Table 1. 
 
 
Controls 
(n=22) 
Fontan  
(n=8) 
Tetralogy  
(n=9) 
Liver  
(n=8) 
p  
Female n(%) 12 (54.5) 3 (37.5) 5 (55.6) 8 (100)  
Age (years) 27.9 (22.4-40.8)†   34.5 (23.1-45.8)  39.9 (37.5-58.4)† 52.0 (39.2-64.7)  0.001 
BMI (kg/m2) 25.6 (23.1-27.2)† 22.7 (21.3-24.1)  27.0 (24.6-29.5) 27.5 (23.6-31.4) 0.012 
SBP (mmHg) 122 (106-138)  113 (103-123)  116 (110-147)† 123 (110-136) 0.630 
DBP (mmHg) 77 (66-89)  74 (69-78)  73 (61-85) 74 (62-86) 0.706 
Heart Rate 
(bpm)  
69 (59-79)  73 (65-81)  70 (57-82) 76 (65-86) 0.399 
Pulse 
Oximetry (%) 
99 (98-99)† 95 (90-99)  98 (97-99)† 99 (97-99)† 0.004 
Relevant 
surgery* n(%) 
0 (0)  5 (62.5) 1 (11.1)  0 (0)   
 
Table 1. Subject Demographics [*Blalock-Taussig Shunt or coarctation repair, BMI: body mass index, SBP: 
systolic blood pressure, DBP: diastolic blood pressure, bpm: beats per minute] 
†Non-normal data.  
 
 
Comparison of tissue StO2 in right and left arms  
CHD patients have often had previous operations that affect blood flow to the aortic arch and 
upper limbs, e.g Blalock-Taussig shunt or repair of coarctation of the aorta (Table 1). We 
therefore asked if there would be differences in the StO2 measurements in the left compared 
with the right arm. There was no overall difference between StO2 measurements in each arm 
in the patients known to have had such operations and in the overall cohort (Table 2). A 
difference in superficial StO2 between right and left arms  (67.7% vs 68.8%, p=0.031) was 
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observed in the healthy control group, but this was not felt to be of clinical significance, and 
not seen in the patient groups (Table 2). It is unclear whether this difference is due to the 
effects of hand dominance, as there were insufficient individuals that were left-handed to 
evaluate this; nevertheless this observed difference was small and not clinically significant.    
 
 Superficial Tissue StO2 (%) Deeper Tissue StO2 (%) 
 Right Left p Right Left p 
All Subjects 
67.3 
(58.9-68.8)† 
66.8 
(60.5-71.2)† 
0.101 
83.4 
(80.3-86.3)† 
82.7 
(80.3-85.0)† 
0.057 
Controls 
67.7 
(64.6-69.3)† 
68.8 
(65.9-71.9)† 
0.031 
82.9 
(78.6-87.2) 
83.0 
(81.0-85.1)† 
0.238 
Fontan 
56.8 
(54.7-58.9) 
58.1 
(54.1-62.0) 
0.369 
80.9 
(78.1-83.8) 
80.5 
(78.2-82.7) 
0.436 
Liver 
67.3 
(58.9-68.9)† 
63.3 
(55.0-71.7) 
0.461 
83.9 
(80.9-86.9) 
83.5 
(79.4-87.6) 
0.507 
Tetralogy 
68.7 
(64.5-70.9)† 
65.4 
(52.6-78.2) 
0.496 
85.3 
(82.2-87.2)† 
82.1 
(80.2-86.7)† 
0.359 
 
Table 2. Comparison of Tissue StO2 in Right and Left Arms. †Non-normal data  
 
 
Variation in superficial and deep tissue StO2 according to probe location  
Because Fontan patients have higher systemic vascular resistance and reduced cardiac 
output, microvascular function might be expected to deteriorate with increasing distance 
from the heart. The variation in StO2 from forearm to thenar eminence (approximate distance 
25cm) and from thenar eminence to fingers (average of index and ring, approximated 
distance 14cm) was plotted (Figure 3A and 3B). Variation in StO2 according to measurement 
site follows a similar trend in all groups.  
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Figure 3. A) and B) - variation in superficial and deeper StO2 according to distance from forearm, 
respectively. Labels a, b, and c represent location of probe as shown in figure 2C. C) and D) - 
superficial and deeper StO2 according to diagnostic group, respectively. E) - dStO2 according to 
diagnostic group. Error bars represent mean and standard deviation.  
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Absolute and  differential  StO2 values. 
We next asked if there were differences in the StO2 levels between different patient groups. 
Whilst there was no overall difference between deeper StO2 levels (p=0.112; Figure 3C), a 
significant difference was observed between superficial StO2 levels (p=0.002). Fontan 
patients had significantly lower superficial StO2 measurements compared to healthy controls 
(57.4% vs 67.4%, p=0.002) and tetralogy patients (57.4% vs 65.5%, p=0.016), but not 
compared to the liver group (57.4% vs 63.8%, p=0.313) (Figure 3D).  
 
Deeper tissue StO2 was consistently higher than superficial StO2 in the whole cohort (82.5% 
vs 64.7%, p<0.001). In view of this we next asked if the difference between absolute 
superficial and absolute deep StO2 measurements (dStO2) varied in the four subject groups. 
An overall difference in dStO2 was observed between groups (p=0.001), with Fontan patients 
having significantly greater dStO2 values compared to healthy controls (23.2% vs 15.4%, 
p=0.001) and tetralogy patients (23.2% vs 16.9%, p=0.037), but again not liver patients 
(23.2% vs 20.0%, p=0.504) (Figure 3E).  
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DISCUSSION 
 
This pilot study demonstrates that CHD patients with Fontan circulation have reduced 
superficial StO2, with increased dStO2 compared to healthy controls and patients with 
repaired tetralogy of Fallot. Although a difference in StO2 between arms was seen in the 
healthy volunteers, this was not seen in any patient group. There was also no difference 
seen in the pattern of StO2 variation according to location along the arm amongst the four 
groups. The abundance of low-resistance arteriovenous anastomoses in glabrous skin of 
human palms23 may explain the observation of elevated StO2 in fingertips and thenar 
eminence compared to the forearm (Figures 3A and 3B).  Additionally, we define a normal 
range for StO2 measurements in healthy individuals which can be used to inform the design 
of future studies. In healthy controls, tissue StO2 at the thenar eminence has proven most 
robust in terms of variability and this alongside our results should be considered in designing 
future clinical studies.24 
 A limitation of this study is its size and the heterogeneity of the patients within each 
group, particularly with respect to their stage of disease progression. Demographic 
differences existed between the groups in our study, specifically in age and BMI (Table 1). 
However, other studies have shown that these factors do not influence tissue StO2 at rest. 
Rosenberry, et al25 reported no difference in resting StO2 measurements between young 
(18–35 year old) and older (65–80 year old) subjects, and Soares, et al26 reported no 
difference in measurements between lean (BMI 18-25 kg/m2) and obese (BMI >30 kg/m2) 
individuals. Nevertheless, the low superficial StO2 and increased dStO2 seem to be robust 
findings that indicate possible microvascular dysfunction in the Fontan group. It is possible 
that the failure to produce a difference in stO2 between arms in the patient groups may 
indicate a general circulatory issue or in a fully powered study may disappear. Conversely, 
whilst our current study did not suggest any clinical features that might associate with the 
reduced superficial StO2 observed in the Fontan group, these may appear in a full study. 
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 Superficial StO2 and dStO2 was significantly different in the Fontan group compared 
to healthy controls and the tetralogy group, but not compared to the liver group (Fig. 3C and 
3E respectively). This may indicate that liver dyfunction in Fontan patients contributes to the 
observed peripheral microcirculatory disturbance. A previous study reported reduced resting 
StO2 values in the thenar eminence of liver cirrhosis patients compared to healthy controls 
(75% vs 81%, P=0.009), with more pronounced reductions in late stage patients.27 These 
findings may be due to either the presence of atriovenous shunts in central vessels, or the 
‘splanchnic steal’ phenomenon leading to extrasplanchnic peripheral vasoconstriction. This 
is of interest, as Fontan patients often have advanced liver disease but preserved synthetic 
function making early detection using conventional markers difficult. Alternatively, our 
findings could be explained by a disturbance of vascular tone secondary to the unique 
nature of the Fontan circulation. Several other studies have reported endothelial 
dysfunction10,11,13,28,29 and sympathetic over-activation10,30 in Fontan patients, which may 
combine to produce a pro-vasoconstrictor phenotype.31 The preload sensitivity and inability 
of the Fontan circulation to easily increase overall cardiac output may be responsible for the 
lower superficial StO2 levels and the increased dStO2.  
 The relationship between arterial saturation (SaO2) and tissue  StO2 measurement 
was not explored in this study. StO2 represents the oxygen saturation of haemoglobin 
globally in the microvascular bed of the assessed tissue, and is hence influenced by 
systemic factors such as haemoglobin level and oxygen tension. Fontan patients may have 
a varying degree of arterial desaturation, according to the presence of an atrial fenestration 
and/or collateral circulation which is reflected in the reduced SaO2 observed in our Fontan 
cohort (table 1). 
 Tissue StO2 is a test that is simple to perform and could be carried out in a clinic 
situation if differences were found in the Fontan circulation. The absence of differences in 
StO2 measurements between groups according to position on the arm is important as it 
makes the measurement relatively robust to differences in the site of measurement as 
typically can happen within the clinic situation. A more detailed understanding of the 
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relationship of StO2 and dStO2 with arterial and mixed venous saturations as well as 
haemoglobin in this population is needed. Understanding how StO2/dStO2 values may vary 
with defined exercise regimens may also be useful as one of the key features of the failing 
Fontan circulation is an inability to adapt cardiac output to activity. If shown to be useful, 
incorporation into a prospective longitudinal study may reveal its relationship with clinically 
relevant outcome measures. 
 While the finding of reduced superficial StO2 in the Fontan cohort indicates possible 
microvascular dysfunction, this was not observed in deeper tissue and hence must be 
interpreted with caution. Resting StO2 is a static measurement that reflects the balance 
between demand and supply of oxygen in the assessed tissue and does not provide 
information on the responsiveness of microvessels to stimuli. Dynamic tests such as StO2 
measurements in response to exercise or vascular occlusion-reperfusion would provide 
more information on microvascular responsiveness and hence function. The feasibility of 
such dynamic tests in these patient cohorts must be evaluated before incorporation into 
larger studies.  
 
CONCLUSION 
 
This pilot study indicates the possibility of microvascular dysfunction in the Fontan 
population but does not provide substantial evidence to overtly prove this. Vascular optical 
measurement of tissue StO2 and dStO2 has potential value as a practical measure of 
microcirculatory function in the Fontan circulation patient, and if feasible, dynamic 
measurements might be more informative in this regard. Further evaluation is needed to 
ascertain the physiological correlates of these measures, particularly relationship with 
arterial oxygen saturation, as well as clinical utility in a larger Fontan patient group. 
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